A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment
International Randomised Controlled Trial of Chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Reduced dose-density of denosumab for maintenance therapy of unresectable giant cell tumor of bone: a multicenter phase II study "REDUCE"
In recent years, EORTC has been involved in a number of large practice-changing clinical trials in the field of Soft Tissue and Bone, leading to the registration of drugs to treat sarcomas including gastrointestinal stromal tumors (GIST). The following compounds were investigated within this group (STBSG):
- Imatinib for GIST More information
- Trabectedin for all types of STS
- Pazopanib for non-adipocytic STS More information
- Eribulin for liposarcomas More information More information
Multicentre trials, with large patient numbers to influence clinical practice and address important research topics, evaluated the role of adjuvant chemotherapy in soft tissue sarcoma patients (more information) as well as the role of single-agent doxorubicin versus the combination of doxorubicin plus ifosfamide in advanced and/or metastatic STS patients (more information).
- euroSARC: the synovial sarcoma project EuroJOSS (link) EuroEwing 2012 & rEECurr (link) Joint Action on Rare Cancers
- European Reference Networks (ERN) for rare solid tumours (EURACAN) (link ).
- EORTC-1637 (lms retrospective): retrospective evaluation of first-line treatment for advanced, metastatic or unresectable leiomyosarcomas.
(project leader: lorenzo d’ambrosio)
Status: database open
This is a retrospective research project (rp) to evaluate the activity of doxorubicin as monotherapy as well as in combination with ifosfamide or dacarbazine as first-line treatment for leiomyosarcoma, pleomorphic leiomyosarcoma and undifferentiated sarcoma with smooth muscle differentiation, to potentially guide the design of a prospective randomized study.
As of today, we have already into our database.
Please be noted that we are planning to close the database by the end of march.
- EORTC-1647 (angio. retrospective): retrospective evaluation of adjuvant chemotherapy in angiosarcoma.
(project leader: robin jones)
Research project approved: 23 aug. 2016
The primary objective of the study will be to evaluate the activity of adjuvant chemotherapy in angiosarcoma patients and to potentially guide the design of a prospective randomized study.
Several sites (around 41) from the STBSG are planning to contribute patient data from their clinical practice.
Fondazione IRCCS Istituto Nazionale dei Tumori
Mannheim University Medical Center
The Royal Marsden Hospital
London, United Kingdom
E. Wardelmann - Muenster , DE
Gerhard Domagk Institute of Pathology - University Hospital Muenster
R. Haas - Amsterdam, NL
Chair Local Treatment
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
A. Le Cesne - Villejuif, FR
Chair Systemic Treatment
S. Bauer - Essen, DE
Chair Translational Research
Universitaetsklinikum - Essen
C. Messiou - London , GB
Chair Imaging Subcommittee
Royal Marsden Hospital
C. Honoré - Villejuif, FR
W. van den Houdt - London , GB
Royal Marsden Hospital
I. Desar - Nijmegen , NL
Radboud University Medical Center Nijmegen
N. Hindi - Sevilla, ES
Virgen del Rocio University Hospital
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study
Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial
Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective study based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials